Anatara Lifesciences Limited

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,249,299 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.

Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Chairman Address to Shareholders.

Anatara Lifesciences (ASX:ANR) is pleased to announce that it has appointed Mr Steven Lydeamore as Chief Executive Officer, effective as of 3rd December 2018.

Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th September 2018. The Company's cash position at the end of the quarter stood at $7.1m.

Anatara Lifesciences (ASX:ANR) is pleased to announce that the Australian Pesticides and Veterinary Medicines Authority has registered Detach(R) with the approved label, "To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets".

Anatara Lifesciences (ASX:ANR), a company focused on commercialising innovative products for gut health, is pleased to announce the formation of its Product Development Advisory Board. The Advisory Board consists of five key external experts: Dr Rebecca Burgell, Dr Jakob Begun, Prof Barry Campbell, Assoc Prof Simon Keely and Prof Peter Gibson, who will serve as the Chairman.

Anatara Lifesciences (ASX:ANR) is pleased to release its Annual Report, for the year ended 30th June 2018.

Anatara Lifesciences Ltd (ASX:ANR) announces that Executive Chairman, Dr Mel Bridges has informed the Board of his wish to retire from his role at Anatara with immediate effect and the Board has formally accepted his resignation.

Anatara Lifesciences (ASX:ANR) is pleased to release a new investor presentation following the announcement that Anatara had established an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R).